Research News
Research News
-
Peering Inside the Cell: A New Frontier in HIV Research
A new method of mapping cellular proteins before and after viral infection—a prime example of “spatial proteomics”—could revolutionize strategies to combat HIV.
-
On the Same Page?
Researchers, including amfAR grantee Dr. Rachel Rutishauser, seek to gain insights by harmonizing definitions and conclusions across HIV cure trials.
-
The “French Patient” May Be the Latest Person Cured of HIV
Known as the “French Patient,” a woman who received a stem cell transplant with donor cells without intact CCR5 receptors is likely the latest HIV cure case.
-
Curing HIV—How Far Have We Come?
It can be hard to keep track of the various cases of HIV having been cured or controlled in the absence of antiretroviral therapy. amfAR has put together a helpful summary.
-
Unmasking the Power of the Pediatric Immune System
In a new study, researchers examine the impact of long-term antiretroviral therapy started during infancy on the HIV reservoir.
-
The Second Berlin Patient
The second Berlin Patient HIV cure opens up new possibilities and amfAR researchers are working to make this strategy an accessible, affordable one.
-
Six Researchers, One Goal
New amfAR grants totaling more than $2.5 million support strategies to cure HIV, from immunotherapy to latency-reversing and anti-cancer agents.
-
Inhibiting HIV by Host Cell Targeting Strategies
-
Beyond Stem Cell Transplantation?
amfAR awards grants to researchers—Drs. Jonah Sacha, Elena Herrera-Carrillo, and Alexander Pasternak—who are testing innovative HIV cure strategies.
-
Predicting Changes in the HIV Reservoir
Researchers zero in on a marker, sugar-protein Galectin-9, that might be able to target HIV persistence, the main barrier to a cure for people living with the virus.
-
A Possible New Avenue to a Cure
A study of the Geneva patient, cured of HIV via a transplant with cells susceptible to infection, opens up new possibilities of eradicating the virus.
-
Lenacapavir Looks to Revolutionize HIV Prevention
PURPOSE 2 study results show that a twice-yearly injectable HIV antiretroviral, lenacapavir, is highly effective as PrEP among MSM, transgender women and men who have sex with men, and others.
-
Researchers Identify a Novel Cell Protein that Can Control HIV Growth
Researchers have discovered a cell protein that can restrict the late phases of HIV replication as well as that of pox viruses.
-
Next-Generation PrEP
PURPOSE 1 trial results show that a twice-yearly injectable—lenacapavir for PrEP—is 100% effective at preventing HIV infection among cisgender women and girls.
-
Daily Updates from the 2024 International AIDS Conference
Daily updates of sessions at AIDS 2024 cover research on curing HIV, HIV care, and AIDS policy from amfAR and others.